Your prediction
Takeda Pharmaceutical Co Ltd Stock
A loss of -2.080% shows a downward development for Takeda Pharmaceutical Co Ltd.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 1 users see the criterium "Business model" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | -2.080% | -2.112% | -0.207% | -6.517% | -3.754% | -14.660% | -22.321% |
| Chugai Pharmaceutical Co Ltd | 1.140% | 0.547% | 5.146% | 8.471% | 8.241% | 80.700% | 16.675% |
| Santen Pharmaceutical Corp Ltd. | 0.570% | 1.734% | 4.762% | - | - | - | - |
| Daiichi Sankyo Co Ltd | 0.140% | -4.432% | -6.120% | -34.652% | -32.312% | -40.176% | -33.102% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
